Clinical Trial Update: Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating three fixed doses of intranasal esketamine added to comprehensive standard of care for rapid reduction of symptoms in pediatric major d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• SPRAVATO (ESKETAMINE HYDROCHLORIDE)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Depressive Disorder, Major | Phase 2 | Status: COMPLETED | Results posted: 2024-04-17